Agios Pharmaceuticals: Liver Toxicity Issues May Threaten Thalassemia Approval (Rating Downgrade)
Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.
Disease doctor urges people with fatty liver to try five drinks to avoid cirrhosis
Elevated fat levels in your liver can raise your chances of developing serious health issues, including diabetes, ...